STOCK TITAN

RxSight, Inc. - $RXST STOCK NEWS

Welcome to our dedicated page for RxSight news (Ticker: $RXST), a resource for investors and traders seeking the latest updates and insights on RxSight stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RxSight's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RxSight's position in the market.

Rhea-AI Summary

RxSight, Inc. reported strong first quarter 2024 financial results, with a revenue of $29.5 million, a 69% increase compared to the first quarter of 2023. The company sold 20,218 Light Adjustable Lenses (LAL) and 66 Light Delivery Devices (LDD), showing significant growth in procedure volume and unit sales. Gross profit increased to $20.7 million, operating expenses rose to $31.4 million, and the company reported a net loss of $(9.1) million. However, adjusted net loss improved to $(4.4) million. Cash, cash equivalents, and short-term investments were $125.4 million as of March 31, 2024. RxSight raised its 2024 revenue guidance to $132.0 million to $137.0 million, gross margin guidance to 68% to 70%, and operating expense guidance to $126.0 million to $130.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
-
Rhea-AI Summary

RxSight, Inc., a medical device company specializing in customized vision after cataract surgery, will be presenting at the Bank of America Healthcare Conference on May 15, 2024. The presentation will be available for viewing online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
conferences
-
Rhea-AI Summary
RxSight, Inc., a leading ophthalmic medical device company, will release its first quarter financial results on May 6, 2024. The company will conduct a conference call to discuss the results at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.93%
Tags
conferences earnings
Rhea-AI Summary
RxSight, Inc. launches the Light Adjustable Lens+ (LAL+), offering customized vision post-cataract surgery. The company presents the LAL+ with a modified aspheric anterior surface at the ASCRS meeting, with over 20 scientific papers and presentations. The LAL+ aims to extend the depth of focus, enhancing refractive and visual outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none
-
Rhea-AI Summary
RxSight, Inc. is set to participate in the 23rd Annual Needham Virtual Healthcare Conference. The company will engage in a fireside chat on April 10, 2024, to discuss its vision solutions post-cataract surgery. Interested parties can view the presentation live or archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
conferences
-
Rhea-AI Summary
RxSight, Inc. is set to participate in the 34th Annual Oppenheimer Healthcare Conference, with management scheduled for a fireside chat on March 13, 2024. The company focuses on personalized vision solutions post-cataract surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
conferences
Rhea-AI Summary
RxSight, Inc. reported strong financial results for Q4 2023 and FY 2023 with revenue growth of 78% and 82% respectively. The company's key highlights include increased unit sales of Light Delivery Devices and Light Adjustable Lenses, driving revenue growth. Despite a net loss in Q4, RxSight's adjusted net loss improved significantly. The company provided guidance for 2024 with revenue expected to grow by 44% to 52% compared to 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
Rhea-AI Summary
RxSight, Inc., a leading ophthalmic medical device company, will release its financial results for Q4 and full year 2023 on February 28, 2024. The company's management will discuss the results in a conference call. Participants can register to listen to the call live or access the archived webcast for a year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
conferences earnings
-
Rhea-AI Summary
RxSight, an ophthalmic medical device company (Ticker: RXST), announced preliminary unaudited financial results for Q4 2023 and full-year 2023, with expected revenue of $28.6 million for Q4, up 78% from the prior year, and $89.1 million for the full year, up 82% from the prior year. The company also provided full-year 2024 guidance, anticipating revenue of $128.0 million to $135.0 million, representing 44% to 52% growth over 2023. The gross profit margin is expected to be in the 65% - 67% range, with operating expenses in the range of $125.0 million to $128.0 million, and non-cash expenses in the range of $22.0 million to $25.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
RxSight, Inc. (RXST) announced its participation in the J.P. Morgan Healthcare Conference on January 10, 2024, to present its plans for providing customized vision to cataract surgery patients. The presentation will be available via live and archived webcast on the company's investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
RxSight, Inc.

Nasdaq:RXST

RXST Rankings

RXST Stock Data

2.31B
27.81M
12.99%
90.02%
3.49%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ALISO VIEJO

About RXST

calhoun vision is the world leader in adjustable intraocular lens technology. the company's proprietary technology utilizes light to enable surgeons to change the power of a lens after it has been implanted in the eye. this offers the potential to provide unparalleled visual outcomes and customization to the specific visual needs of each patient. calhoun vision's light adjustable lens technology is an investigational device in the united states and requires fda approval before it can be marketed commercially. the company has completed phases i and ii of the required clinical investigation; the third and final phase of study has commenced, and all subjects have been fully enrolled.